esophageal cancer
Lucid Diagnostics to Raise $15.3M in Registered Direct Offering
The firm intends to use the net proceeds from the offering for working capital and other general corporate purposes.
Researchers Receive $8M NIH Grant to Evaluate Lucid Diagnostics Esophageal Precancer Test
The researchers will conduct a five-year study to evaluate the firm's collection device and test in patients without symptoms of chronic gastroesophageal reflux disease.
The company also recently published multiple new clinical validation studies to support its quest for reimbursement.
Lucid Diagnostics Raises $22M in Convertible Debt Refinancing
The cash raised brings the company’s total holdings to about $33 million, enough to see it through plans to gain reimbursement for its esophageal cancer test.
Previse Awarded $1.8M NIH Grant to Develop Esophageal Cancer Test
The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.